Dabrafenib
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Dabrafenib
Dabrafenib: Known uses and market status in Australia
Summary
The TxGNN model has no candidate indication with a score of 0.99 or higher for Dabrafenib, so there is currently no new predicted indication. The uses recorded for this drug are listed below. They are the drug’s own recorded uses, not model candidates.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 1 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| metastatic melanoma |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 10003L | Tafinlar | Capsule 75 mg (as mesilate) | Valid |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (BRAF kinase inhibitor), not a conventional cytotoxic |
| Myelosuppression Risk | Please refer to the Product Information (PI) warnings and precautions |
| Emetogenicity Classification | Please refer to the Product Information (PI) warnings and precautions |
| Monitoring Items | Please refer to the PI. Cutaneous toxicity, including panniculitis, is a documented concern in the literature above |
| Handling Protection | Please refer to the PI and local handling policies |
Safety Considerations
- Drug Interactions: The interaction screen identified 100 potential interactions. The 20 shown in the data are all rated Moderate: acarbose, famotidine, ranitidine, cimetidine, hydrocortisone, triamcinolone, dexamethasone, betamethasone, alogliptin, metformin, pioglitazone, chlorpropamide, acetohexamide, bupropion, aprepitant, clarithromycin, magnesium oxide, aluminium hydroxide, calcium carbonate and cisapride. Acid-reducing agents and antacids, antidiabetic agents and corticosteroids are the main groups to review. CYP3A4 induction by dabrafenib is a likely contributor, but this is not confirmed in the data compiled.
- Class-related cutaneous effects: Panniculitis has been reported with BRAF inhibitors, alone or combined with MEK inhibitors (case series above), so skin monitoring is advisable.
Warnings and contraindications from the Australian product label were not available. Please refer to the TGA-approved Product Information (PI) for full safety information.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.